281 related articles for article (PubMed ID: 21811504)
21. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.
Mascarenhas J; Roper N; Chaurasia P; Hoffman R
Clin Epigenetics; 2011 Aug; 2(2):197-212. PubMed ID: 22704337
[TBL] [Abstract][Full Text] [Related]
23. [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
Wang JY; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1303-9. PubMed ID: 22040993
[TBL] [Abstract][Full Text] [Related]
24. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.
Soura EN; Karikas GA
J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775
[TBL] [Abstract][Full Text] [Related]
25. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy.
Boila LD; Sengupta A
Exp Hematol; 2020 Dec; 92():19-31. PubMed ID: 32950598
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia.
Rüter B; Wijermans PW; Lübbert M
Int J Hematol; 2004 Aug; 80(2):128-35. PubMed ID: 15481440
[TBL] [Abstract][Full Text] [Related]
27. Genetic abnormalities and pathophysiology of MDS.
Hosono N
Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
[TBL] [Abstract][Full Text] [Related]
28. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
McDevitt MA
Semin Oncol; 2012 Feb; 39(1):109-22. PubMed ID: 22289497
[TBL] [Abstract][Full Text] [Related]
29. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
30. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
31. Insights into novel emerging epigenetic drugs in myeloid malignancies.
Chandhok NS; Prebet T
Ther Adv Hematol; 2019; 10():2040620719866081. PubMed ID: 31431820
[TBL] [Abstract][Full Text] [Related]
32. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.
Sandoval JE; Huang YH; Muise A; Goodell MA; Reich NO
J Biol Chem; 2019 Mar; 294(13):4898-4910. PubMed ID: 30705090
[TBL] [Abstract][Full Text] [Related]
33. The role of histone methyltransferase EZH2 in myelodysplastic syndromes.
Xu F; Li X
Expert Rev Hematol; 2012 Apr; 5(2):177-85. PubMed ID: 22475286
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of DNA and Histone Methylation by 5-Aza-2'-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells.
Momparler RL; Côté S; Momparler LF; Idaghdour Y
Front Oncol; 2017; 7():19. PubMed ID: 28261562
[TBL] [Abstract][Full Text] [Related]
35. AML-Associated Mutations in DNA Methyltransferase DNMT3A.
Khrabrova DA; Yakubovskaya MG; Gromova ES
Biochemistry (Mosc); 2021 Mar; 86(3):307-318. PubMed ID: 33838631
[TBL] [Abstract][Full Text] [Related]
36. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
Bacher U; Haferlach C; Schnittger S; Kohlmann A; Kern W; Haferlach T
Ann Hematol; 2010 Jul; 89(7):643-52. PubMed ID: 20195608
[TBL] [Abstract][Full Text] [Related]
37. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
38. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
39. Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia.
Dhall A; Zee BM; Yan F; Blanco MA
Front Oncol; 2019; 9():432. PubMed ID: 31192132
[TBL] [Abstract][Full Text] [Related]
40. The evolving genomic landscape of myeloproliferative neoplasms.
Nangalia J; Green TR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
